Metronomic Capecitabine Maintenance for TNBC: Zhongyu Yuan, MD

Metronomic capecitabine maintenance therapy has been shown to be more effective compared with observation for patients with triple-negative breast cancer (TNBC), according to a study led by Zhongyu Yuan, MD. Results of the study have been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this interview with i3 Health, Dr. Yuan shares insights on treating TNBC and future directions in the TNBC treatment landscape. What are the most challenging aspec...
Continue reading

Nivolumab FDA Approved for Esophageal Squamous Cell Carcinoma

Nivolumab (Opdivo®, Bristol Myers Squibb) is now FDA approved for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior fluoropyrimidine- and platinum-based chemotherapy. Previously approved for metastatic non-small cell lung cancer, melanoma, and advanced renal cell carcinoma, among others, nivolumab is an immunotherapy that works by helping immune cells discover and attack cancer cells by inhibiting a cancer cell's abili...
Continue reading

FDA Approves Nivolumab/Ipilimumab/Platinum-Doublet Chemotherapy: NSCLC

Nivolumab (Opdivo®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb) in combination with 2 cycles of platinum-doublet chemotherapy has been FDA approved for treatment-naive patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approval was based on the randomized, open-label trial CHECKMATE-9LA (NCT03215706). A total of 719 patients with met...
Continue reading

Brigatinib Approved for ALK-Positive Non-Small Cell Lung Cancer

For patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), the FDA has approved brigatinib (ALUNBRIG®, Takeda). In addition, the companion diagnostic for brigatinib, Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc.) has also been approved. A next-generation ALK inhibitor, brigatinib works by targeting a broad range of ALK mutations. Approval was based on an open-label, phase 3 trial (NCT02737501) that enrolled 275 patients with locally ...
Continue reading

Ripretinib Approved: Advanced Gastrointestinal Stromal Tumor

The FDA has approved ripretinib (QinlockTM, Deciphera Pharmaceuticals, LLC) for adults with metastatic gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. Gastrointestinal stromal tumor is a rare tumor type with a yearly incidence of around 4,000 to 6,000 in the United States. "Despite the progress that has been made over the past 20 years in developing treatments for GIST, including four FDA-approved targeted therapies––imatinib in...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.